美罗华
环磷酰胺
系统性红斑狼疮
胃肠病学
强的松
泼尼松龙
不利影响
硫唑嘌呤
蛋白尿
咪唑啉
联合疗法
肾病综合征
作者
Domenico Paolo Emanuele Margiotta,Fabio Basta,Veronica Batani,Antonella Afeltra
出处
期刊:BMC Nephrology
[Springer Nature]
日期:2018-03-07
卷期号:19 (1)
被引量:21
标识
DOI:10.1186/s12882-018-0847-z
摘要
The treatment of Lupus Nephritis (LN) is an unmet need in the management of patients with Systemic Lupus Erythematosus (SLE). We report two cases of women affected by Lupus Nephritis (LN) ISN/RNP Class IV with serological active disease, high disease activity and marked fatigue. In both cases, Mycophenolate mofetil (MMF), as induction therapy, was poorly tolerated because of gastrointestinal toxicity. Belimumab, together with low-doses of MMF, was effective as induction treatment leading to early achievement of complete renal response in these two selected cases of LN. We also report a literature review concerning the efficacy and safety of Belimumab in Lupus Nephritis. Further studies are needed to evaluate the use of Belimumab to manage the renal involvement in patients with Systemic Lupus Erythematosus, waiting for the results of ongoing randomized clinical trials.
科研通智能强力驱动
Strongly Powered by AbleSci AI